On another couple of threads, to counter my assertion that Starpharma, led by part-time CEO Jackie Fairley has a history of inept commercialisation of products, disappearing developments, painfully slow trial progress and woeful shareholder communications, @antibotter pointed to the ‘fine print’. The fine print being the forward looking statement disclaimer that comes with Starpharma’s ASX releases.
By this very ‘fine print’ rationale that @antibotter provided, I interpret that Starpharma is not actually obliged to ever provide a future update on the progress or otherwise of its lead internal drug trial of DEP-Docetaxel, or for that matter ever mention DEP-Docetaxel ever again! DYOR
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)